CMS logo

CMS Energy Corporation (CMS)

$74.70

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CMS

Market cap

$23.08B

EPS

3.62

P/E ratio

21.2

Price to sales

2.69

Dividend yield

3.052%

Beta

0.352617

Price on CMS

Previous close

$74.15

Today's open

$74.52

Day's range

$74.37 - $75.45

52 week range

$68.64 - $80.36

Profile about CMS

CEO

Garrick J. Rochow

Employees

8350

Headquarters

Jackson, MI

Exchange

New York Stock Exchange

Shares outstanding

308919602

Issue type

Common Stock

CMS industries and sectors

Utilities

Regulated Utilities

News on CMS

Earnings Preview: CMS Energy (CMS) Q2 Earnings Expected to Decline

CMS Energy (CMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Jul 21, 2026

news preview

CMS Energy's Board of Directors Declares Quarterly Dividend on Common Stock

JACKSON, Mich., July 20, 2026 /PRNewswire/ -- The Board of Directors of CMS Energy has declared a quarterly dividend on the company's common stock.

news source

PRNewsWire • Jul 20, 2026

news preview

Plug This 3% Yield In, Light Up Your Portfolio's Returns: CMS Energy

CMS Energy (CMS) is reaffirmed as a Buy, supported by a $24 billion five-year capex plan driving robust rate base and EPS growth. CMS targets 6–8% annual adjusted EPS growth, with consensus estimates at the high end, and maintains a stable BBB credit rating. Shares trade at a modest 3% discount to fair value, with potential for 9%+ annual total returns through 2031, underpinned by disciplined capital deployment.

news source

Seeking Alpha • Jul 14, 2026

news preview

Will CMS Energy (CMS) Beat Estimates Again in Its Next Earnings Report?

CMS Energy (CMS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

news source

Zacks Investment Research • Jul 14, 2026

news preview

US power companies scramble to secure equipment as surging data center demand strains supplies

Skyrocketing demand from artificial intelligence data centers is exacerbating shortages of critical grid equipment like transformers across the U.S., driving up costs, stretching out wait times and spurring utilities ​and developers to lock in orders far in advance.

news source

Reuters • Jul 9, 2026

news preview

CMS Energy to Announce 2026 Second Quarter Results on July 28

JACKSON, Mich., July 7, 2026 /PRNewswire/ -- CMS Energy announced today it will provide 2026 second quarter results along with a business and financial outlook at 10:00 a.m.

news source

PRNewsWire • Jul 7, 2026

news preview

PPL vs. CMS: Which Regulated Utility Stock is the Smarter Investment?

CMS edges PPL on ROE, capital investment plans and six-month share gains, while both utilities invest in grid upgrades and clean energy.

news source

Zacks Investment Research • Jun 30, 2026

news preview

CMS Energy Announces Chris Shellberg as Vice President of Low-Voltage Electric Distribution

JACKSON, Mich., June 24, 2026 /PRNewswire/ -- CMS Energy announced today that Chris Shellberg has been named vice president of low-voltage electric distribution, effective July 1.

news source

PRNewsWire • Jun 24, 2026

news preview

Tria Federal Appoints Former CMS and IRS CIO Rajiv Uppal to Advisory Board

ARLINGTON, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Tria Federal today announced the appointment of Rajiv Uppal, former Chief Information Officer of the Centers for Medicare & Medicaid Services (CMS) and the Internal Revenue Service (IRS), to the company's Advisory Board.

news source

GlobeNewsWire • Jun 23, 2026

news preview

CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World's First Bispecific Antibody for Passive Immunization Against Rabies

SHENZHEN, CHINA, June 22, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS”, or the “Group”) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the “Product”), a Class 1 therapeutic biological product has been approved by the National Medical Products Administration of the People's Republic of China (“NMPA”) and the drug registration certificate was obtained on 22 June 2026. The Product is indicated for passive immunization in adults following rabies virus exposure.

news source

GlobeNewsWire • Jun 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in CMS Energy Corporation

Open an M1 investment account to buy and sell CMS Energy Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CMS on M1